The study of response to cancer treatments has benefited greatly from the contribution of different omics data but their interpretation is sometimes difficult. Some mathematical models based on prior biological knowledge of signaling pathways facilitate this interpretation but often require fitting of their parameters using perturbation data. We propose a more qualitative mechanistic approach, based on logical formalism and on the sole mapping and interpretation of omics data, and able to recover differences in sensitivity to gene inhibition without model training. This approach is showcased by the study of BRAF inhibition in patients with melanomas and colorectal cancers who experience significant differences in sensitivity despite similar...
Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy i...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
SummaryDespite the development of potent RAF/mitogen-activated protein kinase (MAPK) pathway inhibit...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
Cancer patients often respond very differently to any given drug. Some patients respond very well, w...
International audienceCutaneous melanoma is a highly invasive tumor and, despite the development of ...
Cancer therapeutic regimens are gradually changing from using relatively unspecific cytotoxic agents...
Melanoma is a highly aggressive tumor with a strong dependence on intracellular signaling pathways. ...
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF ...
<div><p>Fifty percent of cutaneous melanomas are driven by activated <i>BRAF</i><sup>V600E</sup>, bu...
Melanoma is the deadliest form of skin cancer, and incidence has continued to increase. Half of all ...
Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lea...
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF ...
Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy i...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy i...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
SummaryDespite the development of potent RAF/mitogen-activated protein kinase (MAPK) pathway inhibit...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
Cancer patients often respond very differently to any given drug. Some patients respond very well, w...
International audienceCutaneous melanoma is a highly invasive tumor and, despite the development of ...
Cancer therapeutic regimens are gradually changing from using relatively unspecific cytotoxic agents...
Melanoma is a highly aggressive tumor with a strong dependence on intracellular signaling pathways. ...
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF ...
<div><p>Fifty percent of cutaneous melanomas are driven by activated <i>BRAF</i><sup>V600E</sup>, bu...
Melanoma is the deadliest form of skin cancer, and incidence has continued to increase. Half of all ...
Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lea...
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF ...
Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy i...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy i...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
SummaryDespite the development of potent RAF/mitogen-activated protein kinase (MAPK) pathway inhibit...